Who is sponsoring NCT03318081?

NCT03318081 is sponsored by Shanghai Mental Health Center.

What drugs are being tested in NCT03318081?

Interventions in NCT03318081: cognitive function rehabilitation and bias modification.

What condition does NCT03318081 study?

NCT03318081 studies Amphetamine Addiction.

Is NCT03318081 still recruiting?

NCT03318081 is currently completed. Last updated 13 January 2020.

Last reviewed 2020-01-13 · How we verify

NCT03318081

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction

Completed NA Last updated 13 January 2020

What this trial tests

NA trial testing cognitive function rehabilitation and bias modification in Amphetamine Addiction in 40 participants. Completed in 1 May 2018.

Timeline

20 October 2017

Primary endpoint
31 December 2017

1 May 2018

Quick facts

Lead sponsor	Shanghai Mental Health Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	20 October 2017
Primary completion	31 December 2017
Estimated completion	1 May 2018
Sites	1 location across China

Drugs / interventions tested

cognitive function rehabilitation and bias modification

Conditions studied

Amphetamine Addiction — all drugs for Amphetamine Addiction →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 60, any sex, with Amphetamine Addiction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The computerized cognitive rehabilitation therapy will be used to treat amphetamine-type stimulant (ATS) addiction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Newly Designed Mobile-Based Computerized Cognitive Addiction Therapy App for the Improvement of Cognition Impairments and Risk Decision Making in Methamphetamine Use Disorder: Randomized Controlled Trial.
Zhu Y, Jiang H, Su H, Zhong N, et al · · 2018 · cited 33× · PMID 29925497 · DOI 10.2196/10292

Verify or expand the search:

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03318081 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 13 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03318081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing